- Home
- VOR vs SABA Comparison
VOR vs SABA Comparison
Compare VOR & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$8.13
Company Overview
Basic Information| Metric | VOR | SABA |
|---|---|---|
| Founded | 2015 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.1M | 240.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VOR | SABA |
|---|---|---|
| Price | $8.13 | $8.76 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $70.43 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 290.0K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.91% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.62 | $3.64 |
| 52 Week High | $65.80 | $4.42 |
Technical Indicators
Market Signals| Indicator | VOR | SABA |
|---|---|---|
| Relative Strength Index (RSI) | 29.79 | 51.30 |
| Support Level | $7.21 | $8.61 |
| Resistance Level | $8.60 | $8.86 |
| Average True Range (ATR) | 0.87 | 0.15 |
| MACD | 0.55 | 0.01 |
| Stochastic Oscillator | 44.80 | 69.36 |
Price Performance
Historical Comparison VOR
SABA
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.